Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia
- Assouline, Sarit
- Buccheri, Valeria
- Delmer, Alain
- Mcintyre, Christine
- Brewster, Michael
- Catalani, Olivier
- Hourcade Potelleret, Florence
- Sayyed, Pakeeza
- Badoux, Xavier
- GAIDANO, Gianluca
DOIAbstract
The aim of the phase Ib, two part SAWYER study (BO25341; NCT01292603) was to investigate the pharmacokinetics and safety of subcutaneous (s.c.) rituximab compared with intravenous (i.v.) rituximab, both in combination with fludarabine and cyclophosphamide (FC), as first line treatment for patients with chronic lymphocytic leukaemia (CLL)
Add to ORKG